Oncoinvent
Manufacturing · Norway · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Gullhaugveien 7, Oslo, Oslo, 0484, Norwa...Phone Number
+47 22183305Website
www.oncoinvent.comRevenue
<$5 MillionStock Symbol
ONCIN.OLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Oncoinvent
Oncoinvent is dedicated to developing innovative radiopharmaceutical products aimed at improving treatment options for cancer patients. Their lead product, Radspherin, utilizes inorganic microparticles as carriers of alpha-emitters to deliver high-power radiation effectively within the peritoneal cavity. The company targets healthcare providers and institutions involved in cancer treatment and research. With a strong focus on advancing their clinical programs, Oncoinvent is committed to enhancing cancer care through cutting-edge technology.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncoinvent your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Oncoinvent recently announced quarterly report
Check if Oncoinvent has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Oncoinvent
Check out if Oncoinvent is spiking on competitors!
Click to see if Oncoinvent had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Oncoinvent, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Oncoinvent has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Oncoinvent launches new products
Recommended Actions
Reach out to Masked Content who joined Oncoinvent as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Oncoinvent is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oncoinvent is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncoinvent.
Oncoinvent financials insights
Gather financial insights about Oncoinvent, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$25M
2020
Other Financing Round
$4M
Oncoinvent Tech Stack
A closer look at the technologies used by Oncoinvent
Most Recent Scoops
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Earnings
Earnings, Finance
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Left Company
Executive Move
As previously reported, Anders Månsson, Chief Executive Officer, has recently left the organization.
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Oncoinvent News & Media
Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®
Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025 OSLO, Norway, June 18, 2026 /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting...Oncoinvent ASA: Second half 2025 results
OSLO, Norway, Feb. 26, 2026 /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results....Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer
New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up...Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer
New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Oncoinvent
Sign Up For FreeTo access detailed company insights
Oncoinvent is dedicated to developing innovative radiopharmaceutical products aimed at improving treatment options for cancer patients. Their lead product, Radspherin, utilizes inorganic microparticles as carriers of alpha-emitters to deliver high-power radiation effectively within the peritoneal cavity. The company targets healthcare providers and... Read More
